Fitriakusumah Y, et al. - This is the first comprehensive human study in Asia to investigate the presence of small intestinal bacterial overgrowth (SIBO) and gut microbiota quantification in patients with non-alcoholic fatty liver disease (NAFLD), an emerging disease not only in Western countries, but also in Asian countries, and other metabolic factors evaluating the progression of liver disease using controlled attenuation parameter (CAP)-transient elastography (TE). This investigation was conducted at outpatient’s Hepatobiliary clinic at a tertiary referral university hospital in Jakarta. In the NAFLD population, SIBO, DM, dyslipidemia, obesity, and metabolic syndrome were more prevalent than non-NAFLD. In this cross-sectional study involving 160 subjects, investigators found that SIBO was not related to NAFLD development and progression. In addition, SIBO was not linked to significant hepatic steatosis and fibrosis. Overall, they suggested that SIBO plays a more significant role in obese patients with NAFLD.